They showed that CAR-T cells incorporating CD28.CD3ζ and infused at low doses (1x105 - 2x105) produced significantly higher tumoricidal effects against leukemia development than CAR-T cells with 4-1BB.CD3ζ co-stimulation (17). Here, CD28 is linked to leukemia.